| abstract |
Disclosed is the use of a compound in the preparation of a drug for treating atherosclerosis, wherein the compound comprises one or more of a compound of formula I, Nib2 and a pharmaceutically acceptable salt thereof. Based on the pathogenic mechanism of atherosclerosis and the generation of an inflammatory response, previous studies have shown that the compound may significantly inhibit the foaming of macrophages, reduce the deposition of fatty necrotic substances, reduce plaque formation, and may delay or inhibit atherosclerosis to some extent. |